Drugs / BIIB023
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01943513 | Oct 2013 → Jan 2014 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT01407406 | Sep 2011 → Feb 2012 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT00771329 | Oct 2008 → Apr 2011 | rheumatoid arthritis | Biogen | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01930890 | Nov 2013 → Jan 2016 | lupus nephritis | Biogen | Terminated | No outcome recorded |
| Phase 2 | NCT01499355 | Jul 2012 → Dec 2015 | lupus nephritis | Biogen | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01407406 ↗ |
| Action | Inhibit | “Tumor necrosis factor ligand superfamily member 12 inhibitor” CHEMBL2109598 ↗1“TWEAK-blocking monoclonal antibody BIIB023” PMID 23928094 ↗ Aug 2013 |
| Modality | Monoclonal antibody | “TWEAK-blocking monoclonal antibody BIIB023” PMID 23928094 ↗ Aug 2013 |
| Route | Intravenous | “administered intravenously” NCT00771329 ↗ |
| Target | TNFSF12 | “Tumor necrosis factor ligand superfamily member 12 inhibitor” CHEMBL2109598 ↗ |